Glucagon: difference between revisions
Diff·revision 18 → 19·00:02, 7 Jul 2025
Difference between revision 18 and revision 19 of Glucagon. 2 lines changed; the page grew by 455 bytes.
| Revision 18 — 02:59, 8 Jun 2025 LedeLeander (talk) correct the dose ladder — the maintenance dose is not the maximum dose 6,619 bytes +577 | Revision 19 — 00:02, 7 Jul 2025 SelectTrialSam (talk) add category for the drug class 7,074 bytes +455 | ||
|---|---|---|---|
| 46 | Glucagon is a notoriously difficult peptide to formulate. At neutral pH it aggregates rapidly into amyloid-like fibrils, so the traditional rescue product was supplied as a lyophilised powder with an acidic diluent for reconstitution immediately before use — an arrangement poorly suited to an emergency.{{r|usp1503}} Non-aqueous and analogue-based ready-to-use formulations have since been introduced. | 46 | Glucagon is a notoriously difficult peptide to formulate. At neutral pH it aggregates rapidly into amyloid-like fibrils, so the traditional rescue product was supplied as a lyophilised powder with an acidic diluent for reconstitution immediately before use — an arrangement poorly suited to an emergency.{{r|usp1503}} Non-aqueous and analogue-based ready-to-use formulations have since been introduced. |
| 47 | 47 | ||
| + | 48 | The fibrillation behaviour is a useful reference point for anyone handling research peptides. [[Peptide aggregation|Aggregation]] is not a rare failure mode; it is the expected behaviour of a hydrophobic peptide held near its isoelectric point at concentration, and a solution that has gone faintly hazy after [[Reconstitution of lyophilised peptides|reconstitution]] should be treated as changed material rather than as a cosmetic problem.{{r|usp1503}} | |
| + | 49 | ||
| 48 | == References == | 50 | == References == |
| 49 | {{reflist}} | 51 | {{reflist}} |